Treatment of type III hyperlipoproteinemia

被引：11

作者：

Guyton, JR

机构：

[1] Duke Univ, Med Ctr, Dept Med,Sarah W Stedman Nutr Ctr, Div Metab Endocrinol & Nutr, Durham, NC 27710 USA

[2] Duke Univ, Med Ctr, Sarah W Stedman Nutr Ctr, Dept Pathol, Durham, NC 27710 USA

来源：

AMERICAN HEART JOURNAL | 1999年 / 138卷 / 01期

关键词：

D O I：

10.1016/S0002-8703(99)70239-5

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

收藏

页码：17 / 18

页数：2

相关论文

共 5 条

[1] Comparison of the hypolipidemic effect of gemfibrozil versus simvastatin in patients with type III hyperlipoproteinemia
Civeira, F
Cenarro, A
Ferrando, J
Puzo, J
Garcia-Otín, AL
Mozas, P
Pocoví, M
[J]. AMERICAN HEART JOURNAL, 1999, 138 (01) : 156 - 162
[2] Intermediate-density lipoproteins and progression of carotid arterial wall intima-media thickness
Hodis, HN
Mack, WJ
Dunn, M
Liu, CR
Selzer, RH
Krauss, RM
[J]. CIRCULATION, 1997, 95 (08) : 2022 - 2026
[3] THE HYPOLIPIDEMIC EFFECTS OF LOVASTATIN AND CLOFIBRATE ALONE AND IN COMBINATION IN PATIENTS WITH TYPE-III HYPERLIPOPROTEINEMIA
ILLINGWORTH, DR
OMALLEY, JP
[J]. METABOLISM-CLINICAL AND EXPERIMENTAL, 1990, 39 (04): : 403 - 409
[4] APOLIPOPROTEIN-E - CHOLESTEROL TRANSPORT PROTEIN WITH EXPANDING ROLE IN CELL BIOLOGY
MAHLEY, RW
[J]. SCIENCE, 1988, 240 (4852) : 622 - 630
[5] Mahley RW, 1995, METABOLIC MOL BASES, P1953